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The characteristics of neurological, psychiatric, developmental and substance-use disorders in low- and middle-income coun-
tries are unique and the burden that they have will be different from country to country. Many of the differences are explained 
by the wide variation in population demographics and size, poverty, conflict, culture, land area and quality, and genetics. Neuro-
logical, psychiatric, developmental and substance-use disorders that result from, or are worsened by, a lack of adequate nutrition 
and infectious disease still afflict much of sub-Saharan Africa, although disorders related to increasing longevity, such as stroke, 
are on the rise. In the Middle East and North Africa, major depressive disorders and post-traumatic stress disorder are a primary 
concern because of the conflict-ridden environment. Consanguinity is a serious concern that leads to the high prevalence of re-
cessive disorders in the Middle East and North Africa and possibly other regions. The burden of these disorders in Latin American 
and Asian countries largely surrounds stroke and vascular disease, dementia and lifestyle factors that are influenced by genetics. 
Although much knowledge has been gained over the past 10 years, the epidemiology of the conditions in low- and middle-in-
come countries still needs more research. Prevention and treatments could be better informed with more longitudinal studies 
of risk factors. Challenges and opportunities for ameliorating nervous-system disorders can benefit from both local and regional 
research collaborations. The lack of resources and infrastructure for health-care and related research, both in terms of person-
nel and equipment, along with the stigma associated with the physical or behavioural manifestations of some disorders have 
hampered progress in understanding the disease burden and improving brain health. Individual countries, and regions within 
countries, have specific needs in terms of research priorities. 
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A s outlined in the introduction to this series (see page S151), the proportion of the global burden of disease (GBD) due to neu-rological, mental health, developmental and substance-use 
(NMDS) disorders is rising worldwide1. The type of disorder and rea-
son for increase varies across countries2, regions and populations as 
indicated by the regional differences in disability adjusted life years 
(DALYs; a metric developed to take both mortality and morbidity 
measures into account). DALYs for a disease or health condition are 
calculated as the sum of the years of life lost (YLL) due to premature 
mortality in the population and the years lost due to disability (YLD) 
for people living with the health condition or its consequences (http://
www.who.int/healthinfo/global_burden_disease/metrics_daly). The 
first regional use of DALYs, the regional patterns of disability-free life 
expectancy and disability-adjusted life expectancy, were reported by 
the Global Burden of Disease Study3.
Opportunities to ameliorate nervous system disorders could be 
increased by both local and regional research collaborations. Lessons 
learned locally, and those learned in collaboration across regions and 
countries, may be adapted and applied to other areas, there may also 
be opportunities to leverage resources. Some disorders have physical 
boundaries, whereas others have sociocultural and economic contexts. 
Thus, the challenges faced in high-income countries are often different 
from those in low- or middle-income countries (LMICs) in type, char-
acteristic or scale. Population demographics, genetics, income, reli-
gion, culture, language, ethnic origin, conflicts, land area and quality, 
and population size vary widely between and within LMICs. Although 
there is some commonality in the prevalence of certain brain disorders 
(Fig. 1), significant diversity exists with respect to the origin, mani-
festation and treatment strategies or options adopted across these re-
gions. In this Review, we focus on sub-Saharan Africa, the Middle East 
and North Africa, Asia, South and Southeast Asia and Latin America4,5. 
We introduce a regional perspective with respect to NMDS disorders, 
highlighting what has been learned from epidemiological differences 
between LMICs as well as globally, while identifying specific needs, 
research priorities and the opportunities for collaboration among dif-
ferent LMICs (Tables 1–4).
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SUB-SAHARAN AFRICA
Malnutrition, from birth through to adulthood, seems to be the most 
significant contributor to disease burden and disability in sub-Saharan 
Africa6. Maternal malnutrition, including micronutrient deficiencies 
such as vitamins and iodine, impairs the development and function 
of the nervous system of offspring, and negative effects can persist 
in the next generation6. Other forms of maternal and environmental 
trauma during the perinatal period affect brain development and cause 
long-term changes in brain function. Neurological disorders caused 
by eating toxic foodstuffs are unique to sub-Saharan Africa. Cassava 
is an important food crop that contains endogenous neurotoxins and, 
if not properly prepared, can cause konzo — a peripheral polyneurop-
athy with prominent sensory loss and ataxia. Lathyrism that presents 
as spastic paraparesis is an equally debilitating neurological disorder 
caused by excessive ingestion of the grass pea Lathyrus sativus that 
contains the excitotoxic amino acid, β-n-oxalyl amino-l-alanine6.
Use of psychostimulants is another major contributor to the bur-
den of brain disorders in sub-Saharan Africa7. Of particular concern 
is the high prevalence of maternal alcohol and methamphetamine use 
in areas such as the Western Cape Province of South Africa. The inci-
dence of fetal alcohol syndrome in some locations within this region 
is the highest in the world8. The increase of methamphetamine use in 
pregnant women in the Western Cape is of concern given the negative 
effects that the drug has on the developing fetus9. Khat use is of con-
cern in East Africa10,11, where 60–90% of men use the drug daily12,13. 
The consequences of habitual khat consumption include behavioural 
disturbances and toxic psychosis, which has a particular impact on the 
overall health of young adults.
The prevalence and incidence of epilepsy in sub-Saharan Africa 
countries is twofold higher than that of other countries14–19. The preva-
lence varies between 4.5 and 20.8 per 1,000 people, owing to the local-
ized and high incidence of parasitic infections, poor perinatal care and 
poor access to treatment. The full burden of epilepsy in sub-Saharan 
Africa is difficult to assess and is likely to be under-reported because 
people with epilepsy are stigmatized and frequently left untreated19. 
Stroke is another concern among non-communicable disorders within 
sub-Saharan Africa — incidence is increasing at an alarming rate20. The 
prevalence of dementia in sub-Saharan Africa is reportedly much low-
er than in other regions21,22. However, these reports may not be a true 
reflection of the prevalence, which it is projected to increase with an 
increase in lifespan. Furthermore, as research extends into rural areas, 
diagnosis of unreported cases may reveal the true burden.
Sub-Saharan Africa has the highest burden of infectious diseases 
and the poorest public health infrastructure in the world6,23. Parasitic 
infections are also highest in this region and often have neurocognitive 
sequelae. HIV-associated neurological disorders area major burden, 
with more than 1.5-million children living with HIV and at risk of de-
veloping HIV-associated cognitive impairment and dementia1,24. Little 
is known of the effects of HIV and antiretroviral treatment on the de-
veloping brain. There is an urgent need for research on the longitudinal 
trajectory of neurodevelopment among children and adolescents who 
are perinatally infected with HIV24. Cognitive and psychiatric problems 
have been found to decrease antiretroviral treatment adherence and 
survival of adults with HIV in Zambia25. Neuroimaging and neurocog-
nitive testing are well established in several regions within sub-Saha-
ran Africa and have been used in cross-country collaborations to fur-
ther our understanding of the spectrum of neurocognitive disorders in 
patients with HIV and to determine the effect of antiretroviral therapy 
on these individuals26. Subtle changes in white-matter integrity have 
been used for early diagnosis and monitoring progression of neurolog-
ical disease in individuals with HIV26.
MIDDLE EAST AND NORTH AFRICA
Many of the aetiological and treatment features of psychiatric disorders 
in the Middle East and North Africa are due, in part, to the unique envi-
ronmental and cultural influences within the region. Over the  past few 
decades, communities have been exposed to traumatic events includ-
ing anti-government uprisings and wars, which has left many pop-
ulations vulnerable to mood disorders, such as post-traumatic stress 
disorder (PTSD) and major depressive disorder (MDD). In comparison 
with the global estimate of 4.4% (ref. 27), depression prevalence in 
Iraq is 7.2% and is 15.3% in the Palestinian territories28,29. In fact, MDD 
is currently listed among the top three causes of YLDs in most of the 
countries within the Middle East and North Africa2. The statistics are 
similar for PTSD within the region.
Owing to the high rate of consanguinity in the region, the in-
cidence of several recessively inherited genetic disorders, such as 
inherited deafness, is increasing30–32. For example, Bardet–Biedl 
syndrome, which includes many nervous system abnormalities, 
is common in most of the Arab countries, particularly in Kuwait. 
Whereas the syndrome typically affects 1 in 150,000 people in North 
America and Europe, the prevalence in Arab countries ranges from 1 
in 13,500 to 1 in 30,000 people30. A national strategy is needed in this 
region to address this burden of genetic disease. Although services 
such as genetic screening exist, understanding the barriers to access 
and use requires implementation research and an understanding of 
sociocultural norms. This will help health workers to tailor services 
and educational campaigns that are culturally acceptable. 
The prevalence of substance-use disorders varies between 7.25% 
and 14.5%, with cannabis being the most commonly used drug fol-
lowed by alcohol2,33. Khat is also widely used as a stimulant in Yemen 
and the neighbouring countries within the Arabian Peninsula.
There is a need for population-based prevalence estimates of 
common neurological disorders in the Middle East and North Af-
rica, with a special emphasis on epilepsy, because systematic epi-
demiological studies of epilepsy in Asia and Africa have not includ-
ed this region34. Most published studies only report hospital-based 
samples35. For example, a review of seizure disorders in Arab coun-
tries indicated a median prevalence of 2.3 per 1,000 people (range, 
0.9–6.5 per 1,000). These figures are very likely to underestimate 
the prevalence in a population of more than 350-million peo-
ple36, particularly because epilepsy is stigmatized within several 
communities37.
Figure 1 | Comparison of disability associated life years (DALYs) between 
high-income and low- and middle-income countries. The data were derived from 
the World Health Organization (http://www.who.int/healthinfo/global_bur-
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LATIN AMERICA AND THE CARIBBEAN 
Within the countries and territories of Latin America and the Caribbe-
an (Central America, Mexico and the Latin Caribbean); the non-Latin 
Caribbean and South America there are sub-regional differences in the 
contribution of NMDS disorders  to the total burden of disease meas-
ured in DALYs. Although DALYs owing to neurological disorders, in-
cluding stroke, are low in the Andean Latin American sub-region, they 
are higher in the southern Caribbean sub-regions and even higher in 
tropical Latin America and the Caribbean. However, if one considers 
the total region, the burden of NMDS disorders accounts for 22.2% of 
the total DALYs. The overall weighted prevalence of mental health dis-
orders in children in the region (12.7%) is significantly more than the 
prevalence (9.7%) seen in United Kingdom when similar diagnostic 
procedures are used38. Importantly, there is inadequate information on 
risk and protective factors that affect the incidence of mental health 
disorders in children living in developing countries in general and Lat-
in America and the Caribbean in particular39.
Unipolar depressive disorders (13.2%) and alcohol dependence 
(6.9%) constitute the most common psychiatric disorders40 in Latin 
America and the Caribbean (Fig.1). The annual level of alcohol con-
sumption (8.4 litres per capita annually) is the second highest in the 
world after Europe41. Alcohol consumption has been associated with 
roughly a third of intentional and non-intentional accidents42; trau-
matic brain injuries incurred from any type of accident have long-term 
implications for society and for the individual, including impaired at-
tention, depression and economic costs to families43.
As for other regions the current increasing trend in DALYs for 
non-communicable disorders2 suggests that epilepsy and dementia 
are unique in terms of their increasing prevalence. Their prevalence or 
manifestation is increasing in Latin America and the Caribbean. The 
annual incidence of epilepsy according to a collection of 32 commu-
nity-based studies is 77.7 to 190 per 100,000 people each year44, com-
pared with 30 to 50 per 100,000 people in high-income countries. 
Distribution of epilepsy across sub-regions of Latin America and the 
Caribbean also differs; one reason for this is the direct association be-
tween epilepsy and the distribution of neurocysticercosis45. Dementia 
is also widespread46,47, but pockets of early onset Alzheimer’s disease in 
families are apparent in Caribbean Hispanic people who originate from 
Puerto Rico or the Dominican Republic21. Studies on familial types of 
dementia in Latin American countries such as Colombia (Alzheimer’s 
disease) and Venezuela (Huntington’s disease) have shown that both 
non-genetic (nurture) and unrelated genetic factors may have a major 
role in influencing phenotypes48–50. This suggests that even highly pen-
etrant autosomal dominant diseases may be modified by environment 
or lifestyle factors. Although not unique to the region, it is worth noting 
that stroke is the leading cause of death in Ecuador, and in other Latin 
American countries51. Little is known about the prevalence of any of 
these disorders among indigenous Andean or Amazonian populations.
ASIA
Sub-regions of Asia comprise East and Southeast Asia, and incorporate 
the Association of Southeast Asian Nations as well as China, whereas 
South Asia consists of sub-Himalayan countries, including Afghani-
stan, Bangladesh, India, Pakistan and Sri Lanka. About two-thirds of 
the world’s population resides on the Asian continent. India and Chi-
na, because of their size and economic impact, have a major influence 
on the health and trends of the region, and in shaping global health 
statistics, however they are catalogued. Asia’s ethnic diversity, and 
widely disparate socioeconomic development lead to significant var-
iations in the prevalence and burden of NMDS disorders. An epidemi-
ological study52 of epilepsy in 23 Asian countries revealed the lifetime 
prevalence of epilepsy to be 1.5 to 14 per 1,000 people. Infections of the 
nervous system often contribute to epilepsy and prevention of these 
infections is needed to reduce the burden of the condition.
Another major concern is the rising prevalence of dementia; al-
though the number of patients with dementia is predicted to increase 
by 100% between 2001 and 2040 in developed countries, dementia is 
predicted to increase by more than 300% in India, China, South Asia 
and the Western Pacific region21. In India alone, there are 3.7 million 
people with dementia and the numbers are expected to double by 2030 
(ref. 53). In addition, the high burden of cardiovascular risk factors in 
developing countries, including India, contributes to cerebrovascular 
disease such as vascular dementia54.
Asia, in particular South Asia, has the highest stroke mortality 
in the world55. Within Asia, there is a wide variation in stroke preva-
lence56. Rural parts of South Asia have lower stroke prevalence than ur-
ban areas56, and this needs to be examined further in future research57. 
In China, the incidence of stroke differs geographically. A higher inci-
dence of stroke is seen in northern and western areas, and is associat-
ed with a higher prevalence of hypertension and obesity58. Barriers to 
preventing and reducing mortality and disability due to stroke are the 
lack of infrastructure, such as dedicated stroke care units, and aware-
ness57.
Tobacco use — a leading cause of stroke — is a major public health 
issue for East and Southeast Asia. Half of the world’s tobacco consump-
tion takes place in Asia59. Men are more likely to smoke than women; 
and prevalence rates for males range across countries from 36% in Sin-
gapore to 64% in Laos60. Although the neurological and other health 
implications of smoking are well known, many Asian people still 
smoke. Public health measures to reduce smoking are just beginning; 
for example, in June 2005 and October 2008, India and Beijing banned 
indoor smoking in public places and offices, respectively. 
COMMON RESEARCH NEEDS AND CHALLENGES
There are several commonalities within LMICs in terms of disease prev-
alence and the public health and research challenges, although consid-
erable ethnic and geographical diversity exists.  
Lack of robust epidemiological studies
Epidemiological studies, preferably longitudinal, designed to identi-
fy disease burden and risk or protective factors for NMDS disorders, 
are one of the most important research needs in LMICs. These need to 
be complemented by research on health systems and sociocultural ef-
fects, and clinical trials to determine the best interventional strategies. 
Furthermore, rapid urbanization and the associated demographic and 
sociocultural changes in LMICs should be studied with respect to their 
impact on the course and outcome of different brain disorders, espe-
cially mental health illnesses and substance misuse.  A careful analy-
sis of the possible interaction between demographic and sociocultural 
changes, and biological factors is essential to initiate remedial steps to 
contain the progression of these disorders. 
Disproportionate distribution of scientists 
Some countries have a disproportionate share of scientists, with in-
vestment and output concentrated in only a few places. In general, 
Latin America produces more neuroscience and mental health dis-
order publications than the Middle East and Africa. Similar variation 
is seen in the number of neuroscience publications produced in Asia 
(Fig. 2). Between 1996 and 2013, India consistently produced the most 
neuroscience and mental health research publications. Figures also 
reveal that 9.2% of institutions in India produce 80.1% of the publi-
cations. Among Latin American and Caribbean countries, Brazil now 
accounts for more than two-thirds of South America’s entire research 
output, although in terms of articles per capita, it is broadly similar 
to Argentina, Uruguay and Chile. One could leverage this situation by 
promoting intraregional research collaborations to enhance research 
capacity and infrastructure. The top 10 African countries in terms of 
health-research publications from 2000 to 2014 are South Africa, Ni-
geria, Kenya, Uganda, Tanzania, Ethiopia, Ghana, Cameroon, Malawi 
and Senegal61. Although these trends comprised all health research, 
it is likely that mental health publications are ranked similarly in 
sub-Saharan Africa.  
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Insufficient resources for treatment and research
Most countries allocate less than 5% of their health-care budget to the 
treatment of brain disorders62,63. For example the Middle East and North 
Africa, Palestine, Qatar and Egypt, spend only 2.5%, 1% and less than 
1% on brain-disorder treatment, respectively64. The number of mental 
health professionals available in most LMICs is also very low. For ex-
ample, there are only 1.44 psychiatrists per 100,000 people in Egypt. In 
India, 52% of the districts do not have psychiatric facilities, and there 
is an acute shortage of psychiatrists, psychologists and psychiatric so-
cial workers65. Hence people with neuropsychiatric disorders remain 
largely undiagnosed and even when they are diagnosed, they do not 
have access to sustainable, affordable treatment and optimal medi-
cal care66. Although a recent World Bank report indicates that disease 
burden that results from non-communicable causes, including mental 
health disorders, has increased substantially, with major depressive 
disorders at the top of the list (http://www.healthdata.org/gbd/data)2 
there is a severe lack of resources, particularly of trained personnel and 
training facilities67. Given the severe fiscal and human-resource con-
straints for treatment, it is not surprising that research is lagging. The 
current research gap between developed and developing nations is re-
flected in the mental health research output, with LMICs contributing 
to only 6% of international research articles68.
Brain drain
Brain drain is the loss of highly trained people, constituting another big 
challenge to LMICs, and widening the research gap between high-in-
come countries and LMICs. The reasons cited by researchers for their 
exodus are a dearth of funding, poor facilities, and limited or a lack of 
peer groups to provide intellectual stimulation69. Although it may be 
argued that brain drain is a common problem in LMICs across disci-
plines, neuroscience research is particularly affected.  This is because 
unlike core disciplines such as chemistry, physics or mathematics, 
Condition or disease Key affected countries Burden of disease Impact of condition or disease
Nutrition: malnutrition All SSA • 204 million people suffer from hunger80–82
• Highest prevalence of stunting in the world is in 
East Africa (42%) and West Africa 36% based on 
the WHO Child Growth Standards83
• 22% of children are underweight in West Africa83
• Maternal malnutrition impairs the 
development and function of the nervous 
system of offspring and negative effects persist 
in the next generation6
• Malnutrition in infants and children affects 
their growth and cognitive development6,84
Nutrition: the toxic 
nutritional neurological 
disorders konzo (cassava) 
and lathyrism (grass pea)
Cameroon, Central African Republic, 
Democratic Republic of Congo, Tanzania, 
Ethiopia and Mozambique
• Reported estimates show there are around 
6,500 cases of cassava toxicity; unofficial reports 
estimate the number of cases to be at least 100,000 
(ref. 85)
• Leads to difficulty in walking84 and peripheral 
polyneuropathy with prominent sensory loss 
and ataxia6
Ethiopia • Malnutrition may increase the negative impact 
of food borne toxins and causes irreversible 
spasticity86.
Substance use: cannabis, 
methamphetamine, khat, 
alcohol, and opiods or 
heroin
West and Central Africa (notably), and South 
Africa
• Cannabis use is higher than the global average 
(12.4% versus 3.8%)87
• Cannabis is the most popular illicit drug followed 
by cocaine 
• 1 in 18 problem drug users receive treatment; 
most of those in treatment are cannabis users87
South Africa • Increased use of methamphetamine during 
pregnancy8,9,88
• General increase in drug use87
• Structural (volume reductions in the striatum 
and increases in limbic areas of the brain) 
and functional deficits as well as cognitive 
and behavioural abnormalities have been 
described in infants and children exposed to 
methamphetamine prenatally9
• Violent behaviour in adults 
• Cognitive dysfunction89
Tanzania, Kenya, Uganda, Ethiopia, Eritrea and 
Somalia
• 60–90% of East African males use khat daily10–13,89 • Chronic khat use may have a long-term 
deleterious effect on working memory90
South Africa • Self-reported prevalence of alcohol abuse is 36.9% 
• Fetal alcohol syndrome in the local Western Cape 
population is the highest in the world8
• Negative effects on the developing fetus9
• Fetal alcohol syndrome, growth retardation 
and cognitive dysfunction8
West and Central Africa and South Africa • Annual prevalence of heroin use is above the 
global average88
• 0.92–2.29 million people used opiates in the past 
year87
• An increasing role as a transit area for drug 
trafficking and increased crime rate87
Epilepsy All SSA • Prevalence varies between 4.5 and 20.8 per 1,000 
people; about twice that elsewhere14–19
• Impaired cognitive function due to effect of 
seizures on the developing brain91
• Stigma and social isolation19
Stroke All SSA • Community-based studies revealed an age-
standardized annual stroke incidence rate of up 
to 316 per 100,000 of the population, and age-
standardized prevalence rates of up to 981 per 
100,000 (ref. 92)
• 65% of all neurological admissions to hospitals are 
stroke related in the West African sub-region92
• Increased burden to society
Dementia Nigeria, Democratic Republic of Congo, 
Senegal, Central African Republic, Tanzania, 
Zambia and Kenya
• Prevalence is between <1% and 10.1% in 
population-based studies and up to 47.8% in 
hospital-based studies93
• A burden to family and society
HIV-associated 
neurological conditions
South Africa, Kenya, Nigeria, Zambia, Malawi, 
Cameroon, Botswana and Uganda,
• 1.5-million children are living with HIV and are 
at risk of developing HIV-associated cognitive 
impairment and dementia3,24
• Prevalence of HIV-related neurocognitive 
impairment ranged from <1% to 80% in hospital-
based studies93
• HIV-related dementia is a particular concern, 
and burden, in SSA as people live longer with 
the disease 
• Children infected with HIV perinatally do not 
perform as well as non-infected children on 
cognitive tests and are at much higher risk for 
psychiatric disorders later in life24
SSA, sub-Saharan Africa; WHO, World Health Organization. The 2014 population estimates for sub-Saharan Africa were 961.5 million (http://data.worldbank.org/region/SSA)
Table 1 | Neurological, mental health, developmental and substance-use disorders and specific burden of disease in sub-Saharan Africa
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neuroscience is an interdisciplinary field and most LMICs do not have 
adequate training capacity. This, combined with the fact that the ex-
pensive infrastructure needed for some areas of brain research is of-
ten not available, drives many researchers from LMICs to migrate to 
high-income countries.
REGION SPECIFIC RESEARCH NEEDS AND CHALLENGES
There are specific needs across the regions that constitute LMICs, which 
have to be addressed in a region- and/or country specific manner.  
Identification of risk and protective factors
There is an immediate need to characterize population groups that 
have increased susceptibility or resilience to brain disorders or bet-
ter clinical outcomes, which could lead to the identification of dis-
ease-modifying factors and interventions in other populations. 
Opportunities for research have been observed in different regions. 
For example, the course and outcome of schizophrenia is better un-
derstood in India than in other countries70. The lifetime prevalence 
of PTSD as a major depressive disorder is not significantly greater in 
Southeast Asia compared with other parts of the world1, despite the 
region being a natural disasters-prone region. As a region with sig-
nificant population growth trends, the likely increase in the number 
of people with childhood and adolescent disorders (including learn-
ing disabilities) at one end of the spectrum and increasing lifespan 
that leads to higher incidence of age-related neurodegenerative dis-
orders (including dementia) at the other end make it imperative that 
resources are channelled to research aimed at identifying risk and 
protective factors5,71–73.
Integration of traditional methods of treatment
Assessing the efficacy of indigenous, traditional Chinese medicine and 
Indian Ayurveda medicine for brain disorders is important. Integrating 
traditional Buddhist practices in the treatment of psychiatric disorders, 
such as the integration of mindfulness techniques into cognitive be-
havioural therapy, has created new intervention approaches including 
mindfulness-based cognitive therapy74, mindfulness-based stress re-
duction75, and dialectical behaviour therapy76. Similarly yoga, as an ad-
dition to pharmacological interventions, is beneficial in the treatment 
of schizophrenia and depression77,78.
Collaborations and knowledge generation
Opportunities have been made possible by improvements in infra-
structure in sub-Saharan Africa, which sets the stage for cross-coun-
try collaboration. For example, in addition to South Africa, several 
countries  have neuroimaging facilities, which can be used to analyse 
brain structure and function to aid diagnosis and treatment. Malawi 
has excellent electroencephalography (EEG) services and the capac-
ity to conduct longitudinal studies. Zambia has very good imaging 
Condition or disease Key affected countries Burden of disease Impact of condition or disease
Mood disorders Vietnam, Cambodia and South Asia countries • Depression is the second most common NMDS 
disorder in Vietnam (2.8% prevalence) and 
Cambodia (16.7% prevalence); there is a relatively 
high prevalence (23.6%) in elderly Chinese69,94,95 
• Anxiety is the most common NMDS disorder in 
Cambodia (27.4% prevalence)2,5 
• Prevalence of 16/1,000 population in India96 
• Unipolar depression ranks among the top 10 
disorders2
• Substantial impact on society in general and family 
in particular
• Patients with psychiatric disorders under diagnosed 
and undertreated due to scarcity of physicians97 
coupled with absence of evidence for effectiveness 
of treatment98 
• People with dysthymia have impaired quality of life 
and poor marital adjustment99
Dementia All Asia • Predicted to increase by more than 300% in India, 
China, South Asia and the Western Pacific region21
• 9 million Chinese have dementia100
• The rate in people over 60 was 3.4% in Thailand 
and 3.5% in Indonesia101
• China and India are predicted to have the largest 
number of dementia cases in the next decade21,100
• An estimated 3.7 million Indians have dementia 
and the numbers are expected to double by 2030 
(ref.102)
• People with dementia who live with families puts 
significant burden on carers. None of the carers 
receive carer benefits and have high levels of 
psychological morbidity102
• Annual cost of dementia in China is US$2,384 per 
patient annually103
Stroke All Asia • Prevalence of 45–471 per 100,000 people in South 
Asia56
• Annual stroke mortality in China is 1.6 million, 
approximately 157 per 100,000, which has 
exceeded heart disease as the leading cause of 
death and adult disability104
• Among a sample of five ASEAN countries 
(Indonesia, Myanmar, Vietnam, Thailand and 
Malaysia), stroke was the top cause of death105
• Stroke mortality in South Asia is the highest in the 
world, accounting for more than 40% of global 
stroke deaths57
• Mortality in South Asia is 73 per 100,000 of the 
population57
• Leading cause of death, long-term disability
• Incidence of stroke differs geographically in China — 
there is a higher incidence in northern and western 
areas, which are associated with higher prevalence 
of hypertension and obesity58 
• Rural parts of South Asia have a lower stroke 
prevalence compared with urban areas56
• There are less than 100 stroke care units in South 
Asia57, leading to poor care for patients and 
increased morbidity and mortality
• Barriers to stroke thrombolysis in South Asia include 
a lack of infrastructure, lack of awareness and a lack 
of affordability57, leading to increase in morbidity 
and mortality
Traumatic brain injury All Asia • 44% of the world’s road deaths occur in Asia106
• The incidence rate of TBI in India is 160 per 
100,000; 1.6 million people will sustain a TBI106 
• India has the highest rate of TBI due to falls, and 
accounts for 50% of global falls106
Tobacco use East and Southeast Asia • Prevalence of male smokers ranges from 36% in 
Singapore to 64% in Laos60; the rate is lower in 
women58
• Smoking in children aged between 13 and 15 is 
common in ASEAN60
• Half of the world’s tobacco is consumed in Asia59 
• South Asia has the highest use of smokeless 
tobacco worldwide59
• Chronic nicotine consumption induces neuro-
adaptations in the brain’s reward system that result 
in nicotine dependence107
• Withdrawal from nicotine can include somatic 
symptoms (for example, jumping, shaking, 
abdominal constrictions, chewing, scratching, and 
facial tremors) or affective symptoms (for example 
anhedonia)107 
• Past smokers are prone to relapse for weeks, months 
or even years after cessation107
• Nicotine affects mood and cognition by stimulating 
nicotinic acetylcholine receptors on neurons in the 
brain’s mesolimbic reward system107
ASEAN, Association of Southeast Asian Nations; NMDS, neurological, mental health, developmental and substance-use; TBI, traumatic brain injury. The 2014 population estimates for South Asia were 
1.692 billion and those for East Asia and Pacific region were 2.02 billion
Table 2 | Neurological, mental health, developmental and substance-use disorders and specific burden of disease in South Asia and Southeast Asia
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and neurophysiology (EEG and nerve conduction velocity) facilities 
for adults and children, as well as the capacity for population-based 
studies in rural and urban centres and longitudinal cohort studies. In 
South Africa, a wide range of research techniques have been devel-
oped, including EEG, electromyography, magnetic resonance imag-
ing, diffusion tensor imaging, structural imaging, magnetic resonance 
spectroscopy, positron emission tomography and transcranial mag-
netic stimulation. 
Health budgets and research funding
A lack of adequate funding opportunities for neuroscience research in 
LMICs is a major hindrance to moving the field forward. The dispropor-
tionate designation of health spending in relation to variable national 
gross domestic product in LMICs makes it difficult to sustain or even 
designate research budgets23. For example, the order of the top three 
countries in sub-Saharan Africa — South Africa, Nigeria and Kenya — 
in terms of health research publications has remained unchanged for 
Condition or disease Key affected countries Burden of disease Manifestation of condition or disease 
Unipolar depressive disorder All LAC • One of the most common mental 
illness39, constituting 13.2% of the 
burden of total DALYs
• Represents 35.7% among psychiatric 
disorders and is more prevalent among 
lower-income groups105
• Typical manifestations are irritability, difficulty with 
concentration, fatigue or lack of energy, feelings of 
hopelessness and/or helplessness and sleep problems 
Substance use:
alcohol and tobacco
All LAC • One of the most common psychiatric 
disorders39, constituting 6.9% burden of 
total DALYS
• Chile has the highest consumption rate 
of alcohol and tobacco40 
• Alcohol consumption is a trigger of violence and 
accidents and is associated with 33% of intentional 
accidents and 26% of non-intentional accidents41
• Both associated with acute as well as long-term 
chronic conditions that range from brain damage, 
high blood pressure and stroke to liver and muscle 
diseases108
All LAC (higher in South America) • Prevalence of smoking in men is 31% and 
in women is 17%109
Traumatic brain injury All LAC • The region has one of the highest rates 
of injury mortality in the world110–112
• Has the highest incidence rates of 
traumatic brain injury caused by 
violence106
Epilepsy Honduras, Panamá, Chile, Peru and Colombia • 17.8 (range, 6–43.2) per 1,000 people 
• Incidence is 77.7–190 per 100,000 people 
per year44, whereas in high-income 
countries it is 30–50 per 100,000
• Epilepsy is characterized by the appearance of 
primary generalized or partial seizures that begin 
with a widespread electrical discharge that involves 
one or both sides of the brain at once. Hereditary 
factors are important in many of these seizures
Dementia All LAC including large family groups in the 
Dominican Republic, Colombia, and Venezuela
• 6% of those over 60 years are affected21
• Affects 2 million people, and likely to 
increase47
DALYs, disability adjusted life years; LAC, Latin America and the Caribbean. The 2014 population estimates for Latin America were 521.9 million and for the Caribbean were 7.0 million
Table 3 | Neurological, mental health, developmental and substance-use disorders and specific burden of disease in Latin America and the Caribbean 
Condition or disease Key affected countries Burden of disease Impact of condition or disease
Unipolar depressive disorder All countries • Prevalence between 5–10%113
• 15.3% Palestinian adults and children have 
depression28
• The lifetime prevalence in Iraq is 7.2%27
• Women are more likely to have higher rates 
of depression than men
• Disability, marital dysfunction, loss of 
employment and risk of suicide113
Post-traumatic stress disorder Conflict zone countries • 36% of adults in Iraq suffer from psychological 
trauma as a result of violence114
• A rate of 23.2% has been reported in Palestinian 
populations in the Gaza strip and Nablus district 
in the West Bank28
• Prevalence of 37.1% for Palestinian children115
• Disability, loss of employment, disrupted 
family relationships and risk of substance 
misuse
Substance-use disorders 
(including nicotine, cannabis, 
alcohol and opiates)  
All countries • 80% of men and 67.8% of women in Yemen have 
used khat during their lifetime
• There has been an increase in the prevalence 
of substance use in the Arabian Peninsula and 
East Africa, particularly among young adults and 
females
• Tramadol use is a serious, growing public health 
problem in Egypt and other Middle East and 
North African countries (8.8% use among school 
children in Egypt)116 
• Cannabis is the most commonly used drug  
• In a 10 country study the tobacco smoking rate 
was 31.2%. The highest rates were in Jordan, 
Lebanon, Syria and Turkey117
• Khat is implicated in depression, anxiety, 
psychosis and cognitive dysfunction91,118
• Early first drug use leads to more drug 
problems later in life119
Recessively inherited genetic 
diseases
All countries • Incidence is related to high consanguinity 
rates30–32
• Increased need for medical care
• Reduced lifespan
• Increased family burden30,31 
Epilepsy  All countries • Median prevalence is estimated to be 2.3 per 
1,000 (ref. 36)
• In 23 Asian countries lifetime prevalence of 
epilepsy was 1.5 to 14 per 1,000 (ref. 54)
Prevalence is likely to be underreported because of 
stigma associated with the illness
The 2014 population estimates Middle East and North Africa were 351.4 million.  Population data from World Bank and aggregated by http://data.okfn.org/data/core/population 
Table 4 | Neurological, mental health, developmental and substance-use disorders  and specific burden of disease in the Middle East and North Africa
REGIONAL RESEARCH | RAVINDRANATH ET AL.
S204 19 November 2015 | 7578 | 527
the past 14 years, because of financial constraints imposed by total ex-
penditure on health and the national gross domestic product61. Funding 
for NMDS disorders research is variable and depends on the priorities of 
the government agencies that fund health and/or science and technol-
ogy research in general (where these exist). Three steps could be taken 
to promote neuroscience research in LMICs. First, governmental fund-
ing for research through universities and research institutions should 
be enhanced and encouraged. Second, funds from national and inter-
national non-governmental organizations (NGOs; which contribute up 
to 20% of all external aid for health services in developing countries, 
http://www.imva.org/Pages/biblfrm.htm) could be used to increase 
research opportunities in health and medicine, including epidemiolo-
gy, clinical research, public health services and policy research. Third, 
increased collaboration with regional or international partners could 
lead to more research opportunities and support.
CONCLUSIONS 
Regional variations in the challenges posed by NMDS disorders among 
LMICs means that research priorities need to be addressed coun-
try-by-country, and by regions within countries. There are significant 
gaps between the resources needed for research and those that are cur-
rently available, and a pressing need to strengthen human-resource 
capacity and research infrastructure, while promoting collaboration. 
Global demographic trends point to LMICs as the main work force of 
the future79; it is, therefore, imperative to act expeditiously to reduce 
the enormous burden of brain disorders in these countries. The loss of 
human potential and cost of inaction are unacceptably high.
1. Murray, C. J. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries 
in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet 380, 2197–2223 (2012).
2. Global Burden of Disease Study Collaborators. Global, regional, and national in-
cidence, prevalence, and years lived with disability for 301 acute and chronic dis-
eases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global 
Burden of Disease Study 2013. Lancet 386, 743–800 (2015).
3. Murray, C. J. & Lopez, A. D. Regional patterns of disability-free life expectancy and 
disability-adjusted life expectancy: global Burden of Disease Study. Lancet 349, 
1347–1352 (1997).
4. Whiteford, H. A. et al. Global burden of disease attributable to mental and sub-
stance use disorders: findings from the Global Burden of Disease Study 2010. Lan-
cet 382, 1575–1586 (2013).
5. Whiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V. & Vos, T. The global burden 
of mental, neurological and substance use disorders: an analysis from the Global 
Burden of Disease Study 2010. PLoS ONE 10, e0116820 (2015).
6. Kerac, M. et al. The interaction of malnutrition and neurologic disability in Africa. 
Semin. Pediatr. Neurol. 21, 42–49 (2014).
7. Degenhardt, L., Whiteford, H. & Hall, W. D. The Global Burden of Disease projects: 
what have we learned about illicit drug use and dependence and their contribution 
to the global burden of disease? Drug Alcohol Rev. 33, 4–12 (2014).
8. Hess, A. T. et al. A comparison of spectral quality in magnetic resonance spectros-
copy data acquired with and without a novel EPI-navigated PRESS sequence in 
school-aged children with fetal alcohol spectrum disorders. Metab. Brain Dis. 29, 
323–332 (2014).
9. Kwiatkowski, M. A., Roos, A., Stein, D. J., Thomas, K. G. & Donald, K. Effects of prena-
tal methamphetamine exposure: a review of cognitive and neuroimaging studies. 
Metab. Brain Dis. 29, 245–254 (2014).
10. Odenwald, M. in Neglected Tropical Disease and Conditions of the Nervous System 
(eds Bentivoglio, M. et al.) 293–306 (Springer, 2014).
11. Patel, N. B. in Neglected Tropical Disease and Conditions of the Nervous System (eds 
Bentivoglio, M. et al.) 307–320 (Springer, 2014).
12. Njuguna, J., Olieva, S., Muruka, C. & Owek, C. Khat consumption in Masalani town, 
northeastern Kenya. J. Psychoactive Drugs 45, 355–359 (2013).
13. Warfa, N. et al. Khat use and mental illness: a critical review. Soc. Sci. Med. 65, 
309–318 (2007).
14. Ba-Diop, A. et al. Epidemiology, causes, and treatment of epilepsy in sub-Saharan 
Africa. Lancet Neurol. 13, 1029–1044 (2014).
15. Mustapha, A. F., Preux, P. M., Sanya, E. O. & Akinleye, C. A. The prevalence and sub-
jective handicap of epilepsy in Ilie—a rural riverine community in South West Nige-
ria: a door-to-door survey. Epilepsy Behav. 37, 258–264 (2014).
16. Ngugi, A. K. et al. Prevalence of active convulsive epilepsy in sub-Saharan Africa 
and associated risk factors: cross-sectional and case-control studies. Lancet Neurol. 
12, 253-263 (2013).
17. Osakwe, C., Otte, W. M. & Alo, C. Epilepsy prevalence, potential causes and social 
beliefs in Ebonyi State and Benue State, Nigeria. Epilepsy Res. 108, 316–326 (2014).
18. Wagner, R. G. et al. Prevalence and risk factors for active convulsive epilepsy in rural 
northeast South Africa. Epilepsy Res 108, 782–791 (2014).
19. Wilmshurst, J. M., Birbeck, G. L. & Newton, C. R. Epilepsy is ubiquitous, but more 
devastating in the poorer regions of the world... or is it? Epilepsia 55, 1322–1325 
(2014).
20. Lekoubou, A., Nkoke, C., Dzudie, A. & Kengne, A. P. Stroke admission and case-fatal-
ity in an urban medical unit in sub-Saharan Africa: a fourteen year trend study from 
1999 to 2012. J. Neurol. Sci. 350, 24–32 (2015).
21. Kalaria, R. N. et al. Alzheimer’s disease and vascular dementia in developing coun-
tries: prevalence, management, and risk factors. Lancet Neurol. 7, 812–826 (2008).
22. Mavrodaris, A., Powell, J. & Thorogood, M. Prevalences of dementia and cognitive 
impairment among older people in sub-Saharan Africa: a systematic review. Bull. 
World Health Organ. 91, 773–783 (2013).
23. Sepulveda, J. & Murray, C. The state of global health in 2014. Science 345, 1275–
1278 (2014).
24. Laughton, B., Cornell, M., Boivin, M. & Van Rie, A. Neurodevelopment in perinatally 
HIV-infected children: a concern for adolescence. J. Int. AIDS Soc. 16, 18603 (2013).
25. Birbeck, G. L. et al. Neuropsychiatric and socioeconomic status impact antiretro-
viral adherence and mortality in rural Zambia. Am. J. Trop. Med. Hyg. 85, 782–789 
(2011).
26. Hoare, J. et al. Systematic review of neuroimaging studies in vertically transmitted 
HIV positive children and adolescents. Metab. Brain Dis. 29, 221–229 (2014).
27. Ferrari, A. J. et al. Burden of depressive disorders by country, sex, age, and year: 
findings from the global burden of disease study 2010. PLoS Med 10, e1001547 
(2013).
28. Alhasnawi, S. et al. The prevalence and correlates of DSM-IV disorders in the Iraq 
Mental Health Survey (IMHS). World Psychiatry 8, 97–109 (2009).
29. Espie, E. et al. Trauma-related psychological disorders among Palestinian children 
and adults in Gaza and West Bank, 2005-2008. Int. J. Ment. Health Syst. 3, 21 (2009).
30. Al-Gazali, L. & Hamamy, H. Consanguinity and dysmorphology in Arabs. Hum. 
Hered. 77, 93–107 (2014).
31. Al-Gazali, L., Hamamy, H. & Al-Arrayad, S. Genetic disorders in the Arab world. Br. 
Med. J. 333, 831–834 (2006).
32. Tadmouri, G. O., Al Ali, M. T., Al-Haj Ali, S. & Al Khaja, N. CTGA: the database for 
genetic disorders in Arab populations. Nucleic Acids Res. 34, D602–D606 (2006).
33. Hamdi, E. et al. Lifetime prevalence of alcohol and substance use in Egypt: a com-
munity survey. Subst. Abus. 34, 97–104 (2013).
34. Preux, P. M. & Druet-Cabanac, M. Epidemiology and aetiology of epilepsy in sub-Sa-
haran Africa. Lancet Neurol. 4, 21–31 (2005).
35. Benamer, H. T. & Grosset, D. G. A systematic review of the epidemiology of epilepsy 
in Arab countries. Epilepsia 50, 2301–2304 (2009).
36. Mirkin, B. Population Levels, Trends and Policies in the Arab Region: Challenges and Op-
portunities. Arab Human Development Report http://mait.camins.cat/ET2050_library/
docs/med/arab_population.pdf. (United Nations Development Programme, 2010).
37. Thomas, S. V. & Nair, A. Confronting the stigma of epilepsy. Ann. Indian Acad. Neurol. 
14, 158–163 (2011).
38. Fleitlich-Bilyk, B. & Goodman, R. Prevalence of child and adolescent psychiatric dis-
orders in southeast Brazil. J. Am. Acad. Child Adolesc. Psychiatry 43, 727–734 (2004).
39. Duarte, C. et al. Child mental health in Latin America: present and future epidemio-
logic research. Int. J. Psychiatry Med. 33, 203–222 (2003).
40. Rodriguez, A. et al. Is prenatal alcohol exposure related to inattention and hyper-
activity symptoms in children? Disentangling the effects of social adversity. J. Child 
Psychol. Psychiatry 50, 1073–1083 (2009).
41. World Health Organization. Global Status Report on Alcohol and Health http://apps.
who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf (WHO, 2014).
Figure 2 | Number of neuroscience papers in international peer-reviewed jour-













































































RAVINDRANATH ET AL. | REGIONAL RESEARCH
527 | 7578 | 19 November 2015 S205
42. Borges, G. et al. Alcohol and violence in the emergency department: a regional re-
port from the WHO collaborative study on alcohol and injuries. Salud Publica Mex. 
50 (Suppl 1), S6–S11 (2008).
43. Massey, J. S., Meares, S., Batchelor, J. & Bryant, R. A. An exploratory study of the 
association of acute posttraumatic stress, depression, and pain to cognitive func-
tioning in mild traumatic brain injury. Neuropsychology 29, 530–542 (2015).
44. Burneo, J. G., Tellez-Zenteno, J. & Wiebe, S. Understanding the burden of epilepsy 
in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 
66, 63–74 (2005).
45. Bruno, E. et al. Epilepsy and neurocysticercosis in Latin America: a systematic re-
view and meta-analysis. PLoS Negl. Trop. Dis. 7, e2480 (2013).
46. Nitrini, R. et al. Prevalence of dementia in Latin America: a collaborative study of 
population-based cohorts. Int. Psychogeriatr. 21, 622–630 (2009).
47. Prince, M. et al. The global prevalence of dementia: a systematic review and 
metaanalysis. Alzheimers Dement. 9, 63–75 (2013).
48. Mejia, S., Giraldo, M., Pineda, D., Ardila, A. & Lopera, F. Nongenetic factors as 
modifiers of the age of onset of familial Alzheimer’s disease. Int. Psychogeriatr. 15, 
337–349 (2003).
49. Paradisi, I., Hernandez, A. & Arias, S. Huntington disease mutation in Venezuela: 
age of onset, haplotype analyses and geographic aggregation. J. Hum. Genet. 53, 
127–135 (2008).
50. Pastor, P. et al. Apolipoprotein E4 modifies Alzheimer’s disease onset in an E280A 
PS1 kindred. Ann. Neurol. 54, 163–169 (2003).
51. Feigin, V. L. et al. Global and regional burden of stroke during 1990-2010: findings 
from the Global Burden of Disease Study 2010. Lancet 383, 245–254 (2014).
52. Mac, T. L. et al. Epidemiology, aetiology, and clinical management of epilepsy in 
Asia: a systematic review. Lancet Neurol. 6, 533–543 (2007).
53. Alzheimer’s Disease International. World Alzheimer Report 2009: The Global Prev-
alence of Dementia http://www.alz.co.uk/research/world-report-2009 (ADI, 2009).
54. Shaji, S., Bose, S. & Verghese, A. Prevalence of dementia in an urban population in 
Kerala, India. Br. J. Psychiatry 186, 136–140 (2005).
55. Mehndiratta, M. M., Khan, M., Mehndiratta, P. & Wasay, M. Stroke in Asia: geograph-
ical variations and temporal trends. J. Neurol. Neurosurg. Psychiatry 85, 1308–1312 
(2014).
56. Kulshreshtha, A., Anderson, L. M., Goyal, A. & Keenan, N. L. Stroke in South Asia: a 
systematic review of epidemiologic literature from 1980 to 2010. Neuroepidemiol-
ogy 38, 123–129 (2012).
57. Wasay, M., Khatri, I. A. & Kaul, S. Stroke in South Asian countries. Nature Rev. Neurol. 
10, 135–143 (2014).
58. Xu, G., Ma, M., Liu, X. & Hankey, G. J. Is there a stroke belt in China and why? Stroke 
44, 1775–1783 (2013).
59. Mackay, J., Ritthiphakdee, B. & Reddy, K. S. Tobacco control in Asia. Lancet 381, 
1581–1587 (2013).
60. Dans, A. et al. The rise of chronic non-communicable diseases in southeast Asia: 
time for action. Lancet 377, 680–689 (2011).
61. Uthman, O. A. et al. Increasing the value of health research in the WHO African 
Region beyond 2015 – reflecting on the past, celebrating the present and building 
the future: a bibliometric analysis. BMJ Open 5, e006340 (2015).
62. Razzouk, D. et al. Scarcity and inequity of mental health research resources in low-
and-middle income countries: a global survey. Health Policy 94, 211–220 (2010).
63. Sharan, P. et al. Mental health research priorities in low- and middle-income countries 
of Africa, Asia, Latin America and the Caribbean. Br. J. Psychiatry 195, 354–363 (2009).
64. Okasha, A., Karam, E. & Okasha, T. Mental health services in the Arab world. World 
Psychiatry 11, 52–54 (2012).
65. Goel, D. S., Agarwal, S. P., Icchpujani, R. L. & Shrivastava, S. in Mental Health: An 
Indian Perspective, 1946-2003 (eds S.P. Agarwal et al.) 3–24 (Directorate General of 
Health Services/Ministry of Health and Family Welfare, 2004).
66. Seedat, S. et al. Twelve-month treatment of psychiatric disorders in the South Afri-
can Stress and Health Study (World Mental Health Survey Initiative). Soc. Psychia-
try Psychiatr. Epidemiol. 43, 889–897 (2008).
67. World Health Organization. Atlas: Country Resources for Neurological Disorders 
http://www.who.int/mental_health/neurology/neurogy_atlas_lr.pdf (WHO, 2004).
68. Saxena, S., Paraje, G., Sharan, P., Karam, G. & Sadana, R. The 10/90 divide in mental 
health research: trends over a 10-year period. Br. J. Psychiatry 188, 81–82 (2006).
69. Pang, T., Lansang, M. A. & Haines, A. Brain drain and health professionals. Br. Med. 
J. 324, 499–500 (2002).
70. Padma, T. V. Developing countries: the outcomes paradox. Nature 508, S14–15 
(2014).
71. Dorsey, E. R. et al. Projected number of people with Parkinson disease in the most 
populous nations, 2005 through 2030. Neurology 68, 384–386 (2007).
72. Paddick, S. M. et al. Dementia prevalence estimates in sub-Saharan Africa: compar-
ison of two diagnostic criteria. Glob. Health Action 6, 19646 (2013).
73. Yang, G. et al. Rapid health transition in China, 1990-2010: findings from the Global 
Burden of Disease Study 2010. Lancet 381, 1987–2015 (2013).
74. Irving, J. A. & Segal, Z. V. Mindfulness-based cognitive therapy: current status and 
future applications. Sante Ment. Que. 38, 65–82 (2013).
75. Kabat-Zinn, J. et al. Effectiveness of a meditation-based stress reduction program in 
the treatment of anxiety disorders. Am. J. Psychiatry 149, 936–943 (1992).
76. Linehan, M. M. Dialectical behavior therapy for borderline personality disorder. 
Theory and method. Bull. Menninger. Clin. 51, 261–276 (1987).
77. Manjunath, R. B., Varambally, S., Thirthalli, J., Basavaraddi, I. V. & Gangadhar, B. N. 
Efficacy of yoga as an add-on treatment for in-patients with functional psychotic 
disorder. Indian J. Psychiatry 55, S374–S378 (2013).
78. Rao, N. P., Varambally, S. & Gangadhar, B. N. Yoga school of thought and psychiatry: 
Therapeutic potential. Indian J. Psychiatry 55, S145–149 (2013).
79. Knudsen, E. I., Heckman, J. J., Cameron, J. L. & Shonkoff, J. P. Economic, neurobiologi-
cal, and behavioral perspectives on building America’s future workforce. Proc. Natl 
Acad. Sci. USA 103, 10155–10162 (2006).
80. Bain, L. E. et al. Malnutrition in Sub-Saharan Africa: burden, causes and prospects. 
Pan. Afr. Med. J. 15, 120 (2013).
81. Motadi, S. A., Mbhenyane, X. G., Mbhatsani, H. V., Mabapa, N. S. & Mamabolo, R. L. 
Prevalence of iron and zinc deficiencies among preschool children ages 3 to 5 y 
in Vhembe district, Limpopo province, South Africa. Nutrition 31, 452–458 (2015).
82. Said-Mohamed, R., Micklesfield, L. K., Pettifor, J. M. & Norris, S. A. Has the preva-
lence of stunting in South African children changed in 40 years? A systematic re-
view. BMC Public Health 15, 534 (2015).
83. Black, R. E. et al. Maternal and child undernutrition and overweight in low-income 
and middle-income countries. Lancet 382, 427–451 (2013).
84. Kitsao-Wekulo, P. et al. Nutrition as an important mediator of the impact of back-
ground variables on outcome in middle childhood. Front. Hum. Neurosci. 7, 713 
(2013).
85. Nzwalo, H. & Cliff, J. Konzo: From poverty, cassava, and cyanogen intake to toxi-
co-nutritional neurological disease. PLoS Negl. Trop. Dis. 5, e1051 (2011).
86. Woldeamanuel, Y. W., Hassan, A. & Zenebe, G. Neurolathyrism: two Ethiopian case 
reports and review of the literature. J. Neurol. 259, 1263–1268 (2012).
87. United Nations Office on Drugs and Crime. World Drug Report https://www.unodc.
org/documents/wdr2014/World_Drug_Report_2014_web.pdf. (UN, 2014).
88. Watt, M. H. et al. The impact of methamphetamine (“tik”) on a peri-urban communi-
ty in Cape Town, South Africa. Int. J. Drug Policy 25, 219–225 (2014).
89. Schuurman, N. et al. Intentional injury and violence in Cape Town, South Africa: an 
epidemiological analysis of trauma admissions data. Glob. Health Action 8, 27016 
(2015).
90. Hoffman, R. & al’Absi, M. Working memory and speed of information processing in 
chronic khat users: preliminary findings. Eur. Addict. Res. 19, 1–6 (2013).
91. Duggan, M. B. Epilepsy and its effects on children and families in rural Uganda. Afr. 
Health Sci. 13, 613–623 (2013).
92. Owolabi, M. O. et al. The burden of stroke in Africa: a glance at the present and a 
glimpse into the future. Cardiovasc. J. Afr. 26, S27–S38 (2015).
93. Lekoubou, A., Echouffo-Tcheugui, J. B. & Kengne, A. P. Epidemiology of neurode-
generative diseases in sub-Saharan Africa: a systematic review. BMC Public Health 
14, 653 (2014).
94. Li, D., Zhang, D. J., Shao, J. J., Qi, X. D. & Tian, L. A meta-analysis of the prevalence 
of depressive symptoms in Chinese older adults. Arch. Gerontol. Geriatr. 58, 1–9 
(2014).
95. Ma, X., Li, S. R. & Xiang, Y. Q. An epidemiological survey on depressive disorder in 
Beijing Aria. Chinese J. Psychiatry 40, 100–103 (2007).
96. Malhotra, S. & Patra, B. N. Prevalence of child and adolescent psychiatric disorders 
in India: a systematic review and meta-analysis. Child Adolesc. Psychiatry Ment. 
Health 8, 22 (2014).
97. Saxena, S., Thornicroft, G., Knapp, M. & Whiteford, H. Resources for mental health: 
scarcity, inequity, and inefficiency. Lancet 370, 878–889 (2007).
98. Patel, V. The need for treatment evidence for common mental disorders in develop-
ing countries. Psychol. Med. 30, 743–746 (2000).
99. Subodh, B. N., Avasthi, A. & Chakrabarti, S. Psychosocial impact of dysthymia: a 
study among married patients. J. Affect. Disord. 109, 199–204 (2008).
100. Chan, K. Y. et al. Epidemiology of Alzheimer’s disease and other forms of demen-
tia in China, 1990-2010: a systematic review and analysis. Lancet 381, 2016–2023 
(2013).
101. Jitapunkul, S., Kunanusont, C., Phoolcharoen, W. & Suriyawongpaisal, P. Prevalence 
estimation of dementia among Thai elderly: a national survey. J. Med. Assoc. Thai 
84, 461–467 (2001).
102. Shaji, K. S. et al. The Dementia India Report: Prevalence, Impact, Costs and Services 
for Dementia http://www.alzheimer.org.in/dementia_2010.pdf. (Alzheimer’s and 
Related Disorders Society of India, 2010).
103. Wang, G. et al. Economic impact of dementia in developing countries: an evalua-
tion of Alzheimer-type dementia in Shanghai, China. J. Alzheimers Dis. 15, 109–115 
(2008).
104. Liu, L., Wang, D., Wong, K. S. & Wang, Y. Stroke and stroke care in China: huge bur-
den, significant workload, and a national priority. Stroke 42, 3651–3654 (2011).
105. Alarcon, R. D. Mental health and mental health care in Latin America. World Psy-
chiatry 2, 54–56 (2003).
106. Hyder, A. A., Wunderlich, C. A., Puvanachandra, P., Gururaj, G. & Kobusingye, O. C. 
The impact of traumatic brain injuries: a global perspective. Neurorehabilitation 22, 
341–353 (2007).
107. D’Souza, M. S. & Markou, A. Neuronal mechanisms underlying development of nic-
otine dependence: implications for novel smoking-cessation treatments. Addict. 
Sci. Clin. Pract. 6, 4–16 (2011).
108. Pyne, H. H., Claeson, M. & Correia, M. Gender Dimensions of Alcohol Consumption 
and Alcohol-Related Problems in Latin America and the Caribbean. World Bank Dis-
cussion paper; no. WDP 433 http://www-wds.worldbank.org/external/default/WD-
SContentServer/WDSP/IB/2005/04/25/000112742_20050425144138/Rendered/
PDF/wdp435.pdf. (World Bank, 2002).
109. Champagne, B. M. et al. Tobacco smoking in seven Latin American cities: the CAR-
MELA study. Tob. Control 19, 457–462 (2010).
110. Barreto, S. M. et al. Epidemiology in Latin America and the Caribbean: current situ-
ation and challenges. Int. J. Epidemiol. 41, 557–571 (2012).
REGIONAL RESEARCH | RAVINDRANATH ET AL.
S206 19 November 2015 | 7578 | 527
111. Hyder, A. A. et al. Global childhood unintentional injury surveillance in four cities 
in developing countries: a pilot study. Bull World Health Organ. 87, 345–352 (2009).
112. Puvanachandra, P. & Hyder, A. A. Traumatic brain injury in Latin America and the 
Caribbean: a call for research. Salud Publica Mex. 50 Suppl 1, S3–S5 (2008).
113. Travers, K. U., Pokora, T. D., Cadarette, S. M. & Mould, J. F. Major depressive disorder 
in Africa and the Middle East: a systematic literature review. Expert Rev. Pharma-
coecon. Outcomes Res. 13, 613–630 (2013).
114. World Health Organization. Iraq Family Health Survey Report 2006/7 http://www.who.
int/mediacentre/news/releases/2008/pr02/2008_iraq_family_health_survey_report.
pdf (WHO, 2007).
115. Lavi, T. & Solomon, Z. Palestinian youth of the Intifada: PTSD and future orientation. J 
Am. Acad. Child Adolesc. Psychiatry 44, 1176–1183 (2005).
116. Bassiony, M. M. et al. Adolescent tramadol use and abuse in Egypt. Am. J. Drug Alcohol 
Abuse 41, 206–211 (2015).
117.  Khattab, A. et al. Smoking habits in the Middle East and North Africa: results of the 
BREATHE study. Respir. Med. 106 (Suppl 2), S16–S24 (2012).
118. El-Zaemey, S., Heyworth, J. & Fritschi, L. Qat consumption among women living in 
Yemen. Int. J. Occup. Environ. Med. 5, 109–111 (2014).
119. Momtazi, S. & Rawson, R. Substance abuse among Iranian high school students. Curr. 
Opin. Psychiatry 23, 221–226 (2010).
ACKNOWLEDGMENTS
The authors thank N. Rao at the Centre for Neuroscience, Indian Institute of Science for 
his help  with the manuscript.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests. Financial support for publication 
has been provided by the Fogarty International Center.
ADDITIONAL INFORMATION
This work is licensed under the Creative Commons Attribution 4.0 In-
ternational License. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless 
indicated otherwise in the credit line; if the material is not included under the Creative 
Commons license, users will need to obtain permission from the license holder to repro-
duce the material. To view a copy of this license, visit http://creativecommons.org/licens-
es/by/4.0
